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Background: Generalized anxiety disorder (GAD) is a prevalent health condition which 
seriously affects both patient quality of life and the National Health System. The aim of this 
research was to carry out a post hoc cost-effectiveness analysis of the effect of pregabalin 
versus selective serotonin reuptake inhibitors (SSRIs)/serotonin norepinephrine reuptake 
inhibitors (SNRIs) in treated benzodiazepine-refractory outpatients with GAD.
Methods: This post hoc cost-effectiveness analysis used secondary data extracted from 
the 6-month cohort, prospective, noninterventional ADAN study, which was conducted 
to ascertain the cost of illness in GAD subjects diagnosed according to Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition criteria. Benzodiazepine-refractory 
subjects were those who claimed persistent symptoms of anxiety and showed a suboptimal 
response (Hamilton Anxiety Rating Scale $ 16) to benzodiazepines, alone or in combina-
tion, over 6 months. Patients could switch to pregabalin (as monotherapy or addon) or to 
an SSRI or SNRI, alone or in combination. Effectiveness was expressed as quality-adjusted 
life years gained, and the perspective was that of the National Health System in the year 
2008. A sensitivity analysis was performed using bootstrapping techniques (10,000 resa-
mples were obtained) in order to obtain a cost-effectiveness plane and a corresponding 
acceptability curve.
Results: A total of 282 subjects (mean Hamilton Anxiety Rating Scale score 25.8) were identi-
fied, comprising 157 in a pregabalin group and 125 in an SSRI/SNRI group. Compared with 
SSRI/SNRI, pregabalin (average dose 163 mg/day) was associated with higher quality-adjusted 
life years gained (0.1086 ± 0.0953 versus 0.0967 ± 0.1003, P = 0.334), but increased health care 
costs (€1014 ± 762 versus €846 ± 620, P = 0.166) and drug costs (€376 ± 252 versus 220 ± 140, 
P , 0.001), resulting in an incremental cost-effectiveness ratio of €25,304 (95% confidence 
interval dominant 149,430) per quality-adjusted life years gained for health care costs and 
€25,454 (dominant 124,562) when drug costs were considered alone. Eighty-six percent of 
resamples fell below the threshold of €30,000 per quality-adjusted life years.
Conclusion: This evaluation suggests that pregabalin may be cost-effective in comparison with 
SSRIs/SNRIs in benzodiazepine-refractory outpatients with GAD treated in mental health care 
settings under usual medical practice in Spain.
Keywords: cost-effectiveness, generalized anxiety disorder, benzodiazepine-refractory patients, 
pregabalin, quality-adjusted life years
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Introduction
Generalized anxiety disorder (GAD) is characterized by 
excessive, uncontrolled, and often irrational and dispropor-
tionate concern about daily issues.1 In addition to agitation, 
irritability, difficulty with concentration, muscle tension, 
sleep disturbance, and fatigue, patients also suffer from 
somatic anxiety symptoms, which can be associated with 
both psychiatric and organic disease.2 Usually, subjects 
experience symptoms for 5–10 years before being diagnosed 
with GAD and receiving appropriate treatment.3 Anxiety 
disorders are considered to be the most prevalent psychiatric 
health conditions, with GAD being one of the most common 
in primary care and mental health care settings,4–6 and have 
been reported to account for represent 13% of the conditions 
seen in psychiatric outpatient clinics.7,8 Normal functioning 
in people with GAD is substantially impaired,9,10 and affected 
patients have lower perceived quality of life and a lower 
degree of social functioning than patients with major health 
conditions.11 Misdiagnosis or underdiagnosis, which trans-
lates into late or inappropriate treatment, can lead to a vicious 
circle of exacerbated existing illness and the development 
of new illnesses, fostering further anxiety, demoralization, 
and depression. The chronic nature of GAD and the vicious 
circle of medical and psychiatric conditions make GAD an 
anxiety disorder which causes considerable impairment, 
resulting in high use of health care resources.12–14 Thus, the 
burden of this disease is considerable for the individual and 
for the health care system.
Regardless of the GAD diagnosis, many patients con-
sulting with anxiety symptoms remain symptomatic despite 
using treatments with an anxiolytic effect and, after a few 
months, may become refractory to therapy.15,16 Benzodiaz-
epines have been shown to be useful for rapid, short-term 
relief of somatic symptoms of GAD,17 and are often used to 
help alleviate restlessness associated with initiation of anti-
depressant therapy. However, these agents are restricted to 
short-term use in many countries because of their potential 
for dependency. According to current treatment guidelines,1 
effective pharmacotherapies that may be used on a long-
term basis in patients with GAD include selective serotonin 
reuptake inhibitors (SSRIs), such as paroxetine, escitalo-
pram, and sertraline, serotonergic noradrenergic reuptake 
inhibitors (SNRIs), such as venlafaxine and duloxetine, and 
a calcium channel modulators, pregabalin. Pregabalin is a 
third-generation anticonvulsant drug licensed for the treat-
ment of GAD in Europe.18–21
Nowadays, health policy decision-makers should not 
only be aware of the clinical evidence of the effectiveness 
of a drug, but also of its financial implications, to be able 
to determine the efficiency of new treatments and thus 
make optimal use of existing limited economic resources. 
Economic evaluations are an appropriate method of 
estimating the economic consequences associated with 
management of anxiety disorders.22 Few formal economic 
evaluations of such agents have been reported in the literature 
published to date. The cost-effectiveness of pregabalin versus 
venlafaxine XR was recently examined from the point of view 
of the Spanish National Health System, but this evaluation 
used a simulation model and data from a short-term clinical 
trial,23 which health care decision-makers may consider 
as not being representative of real-world clinical practice. 
Thus, the objective of the present study is to explore the 
relative efficiency of pregabalin versus SSRIs and SNRIs 
in benzodiazepine-refractory outpatients with GAD treated 
according to current medical practice in mental health care 
settings in Spain.24
Methods
Data source
To perform this post hoc cost-effectiveness analysis, data were 
extracted from the 6-month, cohort ADAN (Amplification of 
Definition of ANxiety) study, which assessed the effect of 
broadening the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV) diagnostic criteria for 
GAD according to clinical evolution in the patients, resource 
utilization, and corresponding costs.24 The ADAN study was 
a multicenter, epidemiologic, noninterventional, prospective 
study conducted in Spanish psychiatric outpatient clinics 
between 2007 and 2008. Trained psychiatrists, with at least 5 
years’ experience in the diagnosis of mental health diseases, 
who participated in the study were asked to select consecu-
tive, newly diagnosed GAD patients, according to DSM-IV 
criteria25 and so-called broad criteria, until the predetermined 
sample size was obtained.
Men and women aged years 18 or over, who had provided 
their written informed consent to participate in the study, were 
refractory to previous benzodiazepine therapy, and had not 
been previously treated with pregabalin were included regard-
less of their previous treatment. For the cost-effectiveness 
analysis shown here, only data from patients with a stan-
dard diagnosis of GAD according to DSM-IV criteria were 
included. The reason for doing this is that, to date, broader 
criteria are still pending acceptance by the scientific com-
munity in a new version of the Diagnostic and Statistical 
Manual of Mental Disorders (ie, the DSM-V), so such 
broader criteria are tentative only. Benzodiazapine-refractory 
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patients was defined as having persistent symptoms and/
or suboptimal response, a Hamilton Anxiety Rating Scale 
(HAM-A) scale26,27 score $ 16, and a Clinical Global 
Impression-Severity (CGI-S) score 28 $ 3 at baseline after a 
course of any standard-dose benzodiazepine regimen, alone 
or in combination, given for at least 6 months prior to the 
baseline study visit. In addition to the main objective, the 
ADAN study also assessed self-perceived health-related 
quality of life using the EQ-5D questionnaire,29,30 use of 
health care resources, and related costs.
Economic model design and patient  
data extraction procedure
A cost-effectiveness analysis was performed in this study. 
A cost-effectiveness analysis is a comparative analysis which 
has the purpose of estimating the ratio between the relative 
expenditure (cost) of a health-related intervention and the 
outcomes (effectiveness) it produces. Cost-effectiveness is 
typically expressed as an incremental cost-effectiveness ratio 
(ICER), ie, the ratio between the difference in costs and health 
benefits of two interventions. A threshold, or willingness to 
pay value, is often set by policy-makers, who may decide that 
only interventions within a given ICER threshold range are 
cost-effective, although decisions on funding may be more 
complex and subject to additional factors. In Spain, there 
is generally no accepted cost-effectiveness threshold value. 
However, an ICER # €30,000 per quality-adjusted life year 
(QALY) gained is usually considered cost-effective.31
To conduct this post hoc cost-effectiveness analysis, 
two groups were identified for analysis from the ADAN 
trial,24 which included patients who met the DSM-IV criteria 
for the diagnosis of GAD. Subjects in both cohorts were 
benzodiazepine-refractory and consecutively selected from 
the blinded study database. Patients receiving pregabalin 
(as monotherapy or addon to the existing benzodiazepine 
treatment) from the baseline visit were used to form a 
pregabalin group, and subjects receiving SSRI/SNRI drugs 
were used to form an SSRI/SNRI group. The SSRI/SNRI 
drugs, included paroxetine, venlafaxine, escitalopram, dulox-
etine, mirtazapine, sertraline, fluoxetine, and citalopram, at 
the clinical discretion of the treating physicians. The patient 
disposition is shown in Figure 1.
Resource utilization and costs
Cost refers to the resources used for the intervention, usually 
measured in monetary terms, such as Euros. The cost of each 
treatment arm is equal to the sum of purchased medical and 
nonmedical resources used and unpurchased resources, such 
as the patient’s loss of productivity or unpaid family member/
caregiver support (called “productivity costs” or “indirect 
costs”). For this financial evaluation, we selected a third party 
payer perspective, which is the one from the Spanish national 
health care system for the year 2008.32 Therefore, only health 
care resource utilization and corresponding costs were 
  computed. The time frame used in the model was 6 months, 
as in the ADAN study. Subsequently, no time discounts were 
applied. Health care resource utilization was recorded at 
baseline and at the end-of-trial visit by means of a health care 
resource utilization questionnaire designed ad hoc for this 
study, representing only the noninterventional nature of both 
Patients
ADAN study
3096
New criteria
1281
Criteria
DSM-IV
No treatment
before ADAN study
1815
Receiving anxiolitic
before ADAN study
1578
No antiepileptic
treatment before
ADAN study
1335
No antidepressant
before ADAN study
501
Study treatment
487
PGB treatment
276
+ No SSRI/SNRI
+ SSRI/SNRI
157
125
237
Antiepiliptic treatment
243
Antidepressant treatment
834
Without study treatment
No PGB treatment
14
211
+ SSRI/SNRI
+ No SSRI/SNRI
119
86
Figure 1 Tree decision model with extraction of data from the original ADAN cohort study.
Abbreviations: ADAN, Amplification of Definitiion of ANxiety; Criteria DSM-IV, GAD diagnosis according to DSM-IV criteria; DSM-N, Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition; New Criteria, gAD diagnosis according to new ADAN study criteria; gAD, generalized anxiety disorder; PgB, Pregabalin; SSRI, Selective 
Serotorin Reuptake Inhibitors; SNRI, Serotonin Norepinephine Reuptake Inhibitors.
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the original cohort study and the cost-effectiveness analysis. 
These resources, all related to GAD, included medical visits 
(primary care, specialists, and emergency room visits), days 
of hospitalizations, drug treatment for symptoms of GAD, 
and nonpharmacological treatment for the condition, such 
as physiotherapy, psychotherapy, and relaxation techniques 
(see Table 1).
The cost of health care resource utilization was calcu-
lated by multiplying the number of resources used during 
the study by its unit price (Table 1), and was expressed dur-
ing a 6-month period before the visit when recording took 
place. Thus, from a cost perspective, the study included 
two visits, ie, baseline and end-of-trial visits. The Spanish 
pharmaceutical drug catalog for 2008 was used to obtain the 
unit price of drugs, where cost was estimated as retail price 
plus value added tax of the cheapest generic medication avail-
able, or cheapest pharmaceutical medicinal product when a 
generic medication or reference price was unavailable. The 
cost of nonpharmacological treatments, medical visits, and 
hospitalizations was obtained from the eSALUD33 health care 
costs database for 2008 (Table 1) updated with the 2008 infla-
tion health care rate.34 Finally, some nonpharmacological 
resources were priced according to expert opinion and/or 
directly from the vendor/provider.
Effectiveness measures
The measurements used to determine the efficiency of 
treatments for this cost-effectiveness analysis during the 
6 months of the study were derived from the ADAN trial and 
were expressed as QALY gained, calculated by trapezoidal 
approximation using time trade-off values from the Spanish 
version of the EQ-5D questionnaire.30 The other effectiveness 
measurements were the change in the Spanish version of the 
HAM-A scale,27 such as response rate (percentage of patients 
with a reduction $ 50% at end-of-trial in comparison with 
the baseline intensity of anxiety symptoms assessed using the 
HAM-A scale) and percentage of subjects without anxiety 
symptoms at end-of-trial (HAM-A # 9 points).
The EQ-5D is a standardized health-related quality of 
life scale and is a generic self-reported measure of health 
used frequently in clinical and economic evaluations, the 
details of which are published elsewhere.30 The HAM-A 
is a 14-item scale, with a score between 0 (absence) and 4 
(severe) that explores the patients’ degree of anxiety.26,27 The 
possible score ranges from 0 to 56 points and allows a global 
score and two subscales, one for psychic symptoms and 
the other for somatic symptoms.26,27 HAM-A scores enable 
patients to be classified scores in the following categories: 
#9 “no or minimal anxiety”; 10–15 “mild anxiety”; 16–24 
“moderate anxiety”; and .24 “severe anxiety”. While these 
classifications have not been clinically validated, to the best 
of our knowledge, they have been previously used by oth-
ers.35,36 The CGI-S scale is a seven-point scale that requires 
the clinician to rate the severity of the patient’s illness at the 
time of assessment relative to the clinician’s past experience 
with patients who have the same diagnosis. Considering total 
clinical experience, a patient is assessed on severity of illness 
at the time of rating as: 1, normal, not at all ill; 2, borderline 
mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 
6, severely ill; or 7, extremely ill.28
Cost-effectiveness analysis
The cost-effectiveness analysis was expressed as the 
ICER. It was calculated by dividing the difference in costs 
between pregabalin and SSRI/SNRI and the difference of 
their effectiveness: ICER = (Costpregabalin – CostSSRI/SNRI)/ 
(Effectivenesspregabalin – EffectivenessSSRI/SNRI). To estimate the 
mean ICER with a nonparametric 95% percentile confidence 
interval (CI), bootstrapping (10,000 resamples) techniques 
were applied to draw the cost-effectiveness plane and the 
ICER acceptability curve for the base-case scenario, in 
accordance with Spanish guidelines for economic evaluation 
of health technologies.37 The base-case scenario was the one 
Table 1 Unit costs (€) of health care resources (Spain)
Resources Unit cost (€)
Non pharmacological treatment (per session)
Psychosocial therapya 45.0
Supportive groupsb 23.0
Cognitive-behavioral therapyd 50.0
Psychoanalytical therapyb 50.0
Occupational therapya 12.1
Drug addict rehabilitation therapyc 45.0
Couple therapye 110.0
Psychotherapy dialecticb 45.0
Physiotherapyb 31.0
Rehabilitationb 30.0
Nursing home (per daytime session)a 33.4
Acupuncturea 30.0
Medical (per visit)
Primary care (or general practitioner)a 10.2
Psychotherapista 45.0
Psychiatrista 67.3
Emergency rooma 121.6
Hospitalization (one day)
Hospital stay in Psychiatric warda 272.8
Notes: aOblikue,  2008.  eSALUD.  SOIKOS;33  bFremap,  Mutua  de  Accidentes  de 
Trabajo y Enfermedades Profesionales de la Seguridad Social número 61; 2008; 
cHospital de la Santa Creu i San Pau, Barcelona, Spain; dAEPC, Spanish Association of 
Behavioral Psychology; egeneral Council of Colleges of Psychology of Spain.
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using the original data observed in the trial and was used as a 
source to feed this cost-effectiveness analysis. This approach 
enabled us to obtain the percentage of replications of ICER 
below €30,000 per QALY gained, and therefore could be 
considered as a cost-effective intervention.31
Sensitivity analysis
Two approaches were used to perform the sensitivity   analysis. 
First, a probabilistic sensitivity analysis was performed 
using bootstrapping (10,000 resamples) techniques. The 
probabilistic sensitivity analysis used the data of the base-
case scenario to be replicated 10,000 times to generate a 
probabilistic distribution of possible ICERs; then, allowing 
the estimate of 95% CI, the cost-effectiveness plane and the 
cost-effectiveness acceptability curve. In a second phase, we 
conducted a set of univariate sensitivity analyses using dif-
ferent sensitive variables each time. The sensitive variables 
considered for the univariate sensitivity analyses were health 
care costs, (medical visits, hospitalization, nonpharmacologi-
cal treatment, and drugs), QALY gained, and trial duration 
(from 6 to 12 months). The values of such variables used in 
the base-case scenario were varied by ±50% each time, and 
the cost-effectiveness analysis was then repeated with the new 
value using resample techniques to calculate new ICERs with 
nonparametric percentile CIs. These allowed us to see how 
robust the findings observed in the base-case scenario were.
Statistical analysis
Descriptive statistics were calculated for the continuous 
variables in the study, including the assessment of central 
tendency and dispersion statistics, with a 95% CI when 
possible. The Kolmogorov-Smirnov test was used to check 
whether data demonstrated a Gaussian distribution. In the 
study, patients were classified according to the severity 
of symptoms, with HAM-A scores # 9 indicating “no or 
minimal anxiety”, 10–15 “mild anxiety”, 16–24 “moder-
ate anxiety”, and .24 “severe anxiety”. The percentage of 
patients without anxiety (HAM-A # 9) and the percentage 
considered to be responders (HAM-A reduction $ 50% 
compared with baseline score) were also calculated.
For categorical variables, absolute and relative fre-
quencies were calculated. For comparisons, the Student’s 
t-test and Chi-square test were used for continuous and 
categorical variables, respectively. Analysis of covari-
ance or binary logistic regression models were carried out 
comparing pregabalin versus SSRI/SNRI groups, adjusting 
for baseline scores (CGI and EQ-5D scores) comorbidities 
(percentage of patients with a comorbid depressive disorder), 
and sociodemographic (marital status) data. All statistical 
tests were two-tailed, and an α-error of ,0.05 was accepted 
as statistically significant. Data were analyzed using SPSS 
version 17.0 (SPSS Inc, Chicago, IL).
Results
In this cost-effectiveness analysis, two groups (Table 2) 
were formed. First was the SSRI/SNRI group, not includ-
ing pregabalin, composed of 125 patients (mean baseline 
HAM-A score 25.5 ± 7.4 points) who received SSRI/SNRI 
treatment, or a combination of such therapies with existing 
therapies at the beginning of the study. The mean number of 
drugs used during the study was 2.3 (95% CI, 2.2–2.5), with 
29.6% of patients using lorazepam concomitantly, 24.8% 
alprazolam, 10.4% clonazepam, 9.6% diazepam, and 8.0% 
other benzodiazepines. Second was the pregabalin group, 
composed of 157 patients (mean baseline HAM-A score 
26.1 ± 7.4 points) who were treated with flexible doses of 
pregabalin (,7 5 mg/day, 30.4% of patients; 75–149 mg/day, 
42.6%; 150–300 mg/day, 23.7%; .300 mg/day, 3.4%; aver-
age dose 163 mg/day), in monotherapy or as an addon to 
existing treatment at the beginning of the study. The mean 
number of drugs in this group was 2.0 (95% CI, 1.9–2.2). 
Added to pregabalin, 16.5% of patients were also treated 
concomitantly with alprazolam, 15.2% with lorazepam, 
14.0% with mirtazapine, and 12.1% with diazepam.
Both groups were similar, from a statistical standpoint, with 
regard to main sociodemographic characteristics (Table 2). 
However, clinical characteristics at baseline showed statisti-
cally significant differences in health scales, such as CGI-S 
scores, with scores being higher for the pregabalin group 
(4.2 ± 0.7 versus 3.9 ± 0.7, P = 0.024), and the mean utility 
value and health status assessed by the EQ-5D questionnaire 
being lower for the pregabalin group (0.4760 ± 0.2970 versus 
0.5533 ± 0.2839, P = 0.042), meaning that patients included in 
the pregabalin group started with a more severe baseline status 
than those in the SSRI/SNRI group (Table 2). In addition, at 
baseline, the group of patients assigned to pregabalin had been 
treated with a significantly higher number of antidepressants 
than the control group (22.3% versus 6.4%, P , 0.001).
Total health care costs and effectiveness values 
are included in Tables 3 and 4. Compared with SSRI/
SNRI, pregabalin showed higher numerical QALY gains 
after 6 months of treatment (0.1086 ± 0.0953 versus 
0.0967 ± 0.1003, P = 0.334) after adjusting for gender, age, 
comorbidities, and baseline values. Moreover, the percentage 
of patients showing a response (HAM-A reduction $ 50%) 
at end-of-trial was also numerically higher in the pregabalin 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
161
SSRI/SNRI in benzodiazepine-refractory gADClinicoEconomics and Outcomes Research 2012:4
group (71.5% versus 64.3%, odds ratio = 1.5 [0.9–2.7], 
P = 0.271), but significant differences were not observed in 
the percentage of subjects without anxiety at the end of the 
study. Total health care costs were numerically higher in 
the pregabalin group compared with the SSRI/SNRI group 
(€1014 ± 762 versus €846 ± 620, P = 0.166). This difference 
was mainly due to the medical visit costs and, as expected, 
the cost of drugs (Tables 3 and 4).
The probabilistic ICER of pregabalin over SSRI/SNRI 
drugs in total health care costs was €25,304 per QALY gained 
(95% CI dominant, 149,430, Table 4). The cost-effectiveness 
plane (Figure 2) showed that 68.82% of the resamples fell 
in the upper right quadrant (higher health care costs and 
more QALY gained). The cost-effectiveness acceptability 
curve constructed with those resamples showed that 86% fell 
under the willingness-to-pay threshold of €30,000 per QALY 
(Figure 3). In terms of drug costs only, the probability ICER 
after 10,000 resamples was €25,454 per QALY gained (95% 
CI dominant, 124,562), with 85.0% of samples in the upper 
right quadrant (Figure 2). In this case, 86% of the samples 
fell under the willingness-to-pay threshold of €30,000 per 
QALY gained (Figure 3).
Table 2 Baseline socio-demographics and clinical characteristics of the study series according to treatment group (ADAN study, 
reference 24)
Variable Pregabalin N =157a SSRI/SNRI N =125a P
gender (women), n (%) 89 (61.4%) 70 (60.9%) 0.933
Age (years), mean (SD) 45.7 (13.8%) 44.1 (13.7%) 0.340
Body mass index (kg/m2), mean (SD) 25.0 (3.7%) 24.5 (3.9%) 0.295
Marital status, n (%) 
Married/cohabiting 
Single 
Widow(er) 
Divorced/separated
 
92 (59.0%) 
35 (22.4%) 
13 (8.3%) 
16 (10.3%)
 
82 (65.6%) 
108 (27.2%) 
13 (1.6%) 
34 (5.6%)
0.044 
 
Educational level, n (%) 
No education 
Primary education 
Secondary education 
Intermediate educational level 
Higher education (university) 
Others
 
6 (3.8%) 
49 (31.2%) 
33 (21.0%) 
30 (19.1%) 
36 (22.9%) 
3 (1.9%)
 
2 (1.6%) 
37 (29.8%) 
25 (20.2%) 
28 (22.6%) 
31 (25.0%) 
1 (0.8%)
0.849 
 
 
 
Work status, n (%) 
Active 
Housewife 
Sick leave 
Unemployed 
Retired 
Does not work (students) 
Others
 
89 (56.7%) 
30 (19.1%) 
5 (3.2%) 
16 (10.2%) 
16 (10.2%) 
1 (0.6%) 
0 (0.0%)
 
76 (61.3%) 
25 (20.2%) 
5 (4.0%) 
6 (4.8%) 
7 (5.7%) 
3 (2.4%) 
2 (1.6%)
0.176 
 
 
 
 
Health scales 
CgI score, mean (SD)
 
4.2 (0.7)
 
3.9 (0.7)
 
0.024
HAM-A score, mean (SD) 
Severe (.24), n (%) 
Moderate (16 , HAM-A # 24), n (%)
26.1 (7.4) 
96 (63.6%) 
43 (28.5%)
25.5 (7.4) 
63 (54.8%) 
41 (35.7%)
0.666 
0.091 
0.392
EQ-5D 
Utility value, mean (SD) 
Health status (VAS), mean (SD)
 
0.4760 (0.2970) 
47.5 (15.9)
 
0.5533 (0.2839) 
51.0 (14.6)
 
0.042 
0.139
Previous benzodiazepine, n (%) 
Alprazolam 
Lorazepam 
Diazepam 
Clonazepam 
Bromazepam 
Others
 
49 (31.2%) 
29 (18.0%) 
26 (16.5%) 
25 (15.9%) 
24 (15.2%) 
12 (7.6%)
 
31 (24.8%) 
37 (29.6%) 
12 (9.6%) 
13 (10.4%) 
19 (15.2%) 
10 (8.0%)
 
0.292 
0.040 
0.127 
0.240 
0.883 
0.910
Notes: aTotal number of patients analyzed (some patients failed to report all data).
Abbreviations: ADAN, Amplification of Definition of Anxiety; SSRI, Selective Serotonin Reuptake Inhibitors; SNRI, Serotonin-Norepinephrine Reuptake Inhibitors; p, statistical 
significance; SD, standard deviation; VAS, visual analogue scale; CGI, Clinical Global Impression; HAM-A scale, Hamilton-Anxiety scale; EQ-5D, EuroQol-5 Dimensions Quality 
of Life scale.
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Sensitivity analysis
The sensitivity analysis indicated the ICER to be robust as 
the main variable of the study range ±50% of the base-case 
value and after obtaining 10,000 bootstrap resamples in 
each case (Table 5). In most new scenarios, the probability 
of pregabalin being cost-effective was above 0.86 when the 
willingness-to-pay threshold was set up €30,000 per QALY, 
except when drug costs were multiplied by 1.5 (probability 
decreased to 0.78), or when the study time horizon increased 
up to 12 months (probability 0.80), which could still be con-
sidered cost-effective. When QALY gained was multiplied by 
0.5 (0.50 reduction of the base-case scenario), the probability 
of pregabalin being cost-effective for a willingness-to-pay 
threshold of €30,000/QALY dropped to 70%.
In this evaluation, we also analyzed the group of subjects 
treated with pregabalin in a subanalysis comparing pregabalin 
in monotherapy versus pregabalin as an addon therapy, with 
the aim of determining whether a difference in cost or health 
benefit exists between these two treatment populations at 
baseline and at end-of-trial. This subanalysis (data not shown) 
found that both populations, although unequal, were similar 
and comparable at baseline and at end-of-trial in terms of 
improved quality of life or QALY gain. The only difference, 
as expected, was drug costs, which were higher for patients 
treated with pregabalin plus other additional antianxiety treat-
ments, compared with those treated with pregabalin alone.
Discussion
This paper estimates the cost-effectiveness of treatment for 
GAD with pregabalin or SSRI/SNRI drugs in benzodiaz-
epine-refractory patients in order to provide health decision-
makers with insights on the efficiency of these therapies. The 
design used in this evaluation allowed us to run the analysis 
in GAD patient cohorts with similar sociodemographic and 
clinical characteristics and, interestingly, to collect real 
world data from such patients. This is of particular inter-
est for health decision-makers who have the opportunity 
to support their estimations and decisions in realistic data, 
instead of findings calculated from simulations, modeling, 
or clinical trials only.
Table 3 Health care costs and effects according to treatment group
Variable Pregabalin N = 157a SSRI/SNRIN =125a Adjusted difference/RRb Pc
Health care costs (€), mean (SD) 
  Medical visitsd 
  Hospitalizationd 
  Non pharmacological treatmentd 
  Drugse
1,014 (762) 
398 (518) 
2 (22) 
239 (422) 
376 (252)
846 (620) 
394 (392) 
0 (0) 
233 (325) 
220 (140)
111.9 (-46.6; 270.4) 
-40 (-149.6; 69.5) 
2.3 (-1.4; 6.1) 
2.8 (-72.4; 78.0) 
135.8 (94.7; 176.9)
0.166 
0.473 
0.223 
0.942 
,0.001
Effectiveness (%) 
HAM-A score change with therapy 
  Mean change (%) at end-of-trial 
  Patients without anxiety (HAM-A # 9), % 
  Responders (HAM-A reduction $50%), % 
CgI mean variation (SD) at end-of-trial 
QALYs gained, mean (SD)
 
 
-64.8% 
55.0% 
71.3% 
-1.9 (1.0) 
0.1086 (0.0953)
 
 
-63.7% 
55.7% 
64.0% 
-1.8 (1.0) 
0.0967 (0.1003)
 
 
-1.0 (-7.8; 5.8) 
1.2 (0.7; 2.1) 
1.1 (1.0; 1.3) 
0.1 (-0.2; 0.3) 
0.008 (-0.015; 0.032)
 
 
0.767 
0.552 
0.189 
0.470 
0.487
Notes: aTotal number of patients analyzed; some patients failed to report all data; badjusted by age, sex, co-morbidities and baseline values when applicable or adjusted 
relative risk (RR), in parenthesis, 95% confidence interval; cpower was ,80% in all comparison; dsee table 1 for sources of unit cost sources; ePharmaceutical price list from the 
Catálogo del Consejo General de Colegios Farmacéuticos de España, BOT base de datos del medicamento 2008.
Abbreviations: SSRI, Selective Serotonin Reuptake Inhibitors; SNRI, Serotonin-Norepinephrine Reuptake Inhibitors; p, statistical significance; SD, standard deviation; Health 
care costs, (medical visits + hospitalization + non pharmacological treatments + drugs) costs; HAM-A scale, Hamilton-Anxiety scale; CGI, Clinical Global Impression; QALY 
gained, quality-adjusted life year gained.
Table 4 Cost-effectiveness analysis
Variable Pregabalin N = 157a SSRI/SNRI N = 125a Differenceb
Total health care costs (€), mean (95% CI) 1,014 (894; 1,135) 846 (736; 956) 112 (-40; 270)
Total drug costs (€), mean (95% CI) 376 (338; 415) 220 (195; 244) 136 (95; 177)
Effectiveness (QALY gained), mean (95% CI) 0.1086 (0.0929; 0.1244) 0.0967 (0.0781; 0.1154) 0.008 (-0.015; 0.032)
Probabilistic ICERhealthcare cost (€)c 25,304 (dominant; 149,430)
Probabilistic ICERdrugs (€)c 25,454 (dominant; 124,562)
Notes: aTotal number of patients analyzed (some patients failed to report all data); badjusted by age, sex, co morbidities and baseline values when applicable; cICER calculated 
with bootstrapping techniques after 10,000 resamples with its 95% CI percentile.
Abbreviations: SSRI, Selective Serotonin Reuptake Inhibitors; SNRI, Serotonin-Norepinephrine Reuptake Inhibitors; QALY gained, quality-adjusted life year gained; ICER, 
Incremental Cost-Effectiveness Ratio.
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Although SSRIs, SNRIs, and pregabalin are recommended 
as the primary approaches for treating GAD, benzodiazepines 
are still widely used.16 Benzodiazepines have a rapid onset of 
action, but it is recognized by regulatory authorities and clini-
cal guidelines that their potential for abuse and dependence 
limits their use.17,38 Long-term benzodiazepine use needs to 
be monitored for signs of both dependence and tolerance. 
In addition, many patients still remain symptomatic, or fail 
to respond at all. The existing data and clinical experience 
suggest that alternative or adjunctive use of benzodiazepines 
added to antidepressants or anticonvulsants, such as pregaba-
lin, are reasonable strategies to consider after weighing their 
associated risk profile.16 In this population, adding pregabalin 
to the treatment of such benzodiazepine-refractory patients 
compared with adding SSRI/SNRI drugs showed that treat-
ing subjects with pregabalin would cost about €112 more per 
patient in health care costs over a 6-month period. However, 
this incremental cost was accompanied by better results in 
terms of both increased clinical response (better reduction of 
anxiety symptoms and percentage of responders), and much 
A
B
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400
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0.47%
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2.71%
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85.04% 14.96%
14.00%
Costs (€)
Costs (€)
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Figure 2 Cost-effectiveness plane for total health care cost (graph A) and total drug cost (graph B) of pregabalin over SSRI/SNRI.
Abbreviations: Total health care costs, (medical visits + hospitalization + non pharmacological treatments + drugs) costs; QALY gained; quality-adjusted life year gained. 
SSRI, Selective Serotonin Reuptake Inhibitors; SNRI, Serotonin-Norepinephrine Reuptake Inhibitors.
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better quality of life as assessed by QALY gain (ie, lower 
trade-off of years of perfect health), resulting in an afford-
able increased cost of €25,304 per QALY gained, which 
in our health care context used is considered to be a cost-
effective intervention.31 When this operation was repeated 
to obtain 10,000 samples for management of the level of 
uncertainty, the robustness of the results was confirmed in 
most scenarios included in the sensitivity analysis carried 
out; most of the new incremental cost-effectiveness ratios 
fell below the willingness-to-pay threshold of €30,000 per 
QALY. This indicates that treatment with pregabalin seems 
to be cost-effective compared with SSRI/SNRI treatment in 
benzodiazepine-refractory outpatients with GAD in most 
clinical situations. As expected, the only exception was when 
the QALY gain was reduced by 50% or when the drug costs 
are increased again by 50%, even though those scenarios 
were considered highly unlikely.
In this evaluation, we also analyzed the group of subjects 
treated with pregabalin in a subanalysis comparing pregaba-
lin in monotherapy versus pregabalin as an addon therapy, 
with the aim of determining whether a difference in cost or 
health benefit exists between these two treatment popula-
tions. Because this subanalysis found that both subgroups 
obtained a similar and comparable QALY gain, with the only 
expected difference being in drug costs (higher for patients 
treated with pregabalin plus other additional antianxiety treat-
ments compared with pregabalin alone), the question arises 
regarding whether the effectiveness of “therapy additional to 
pregabalin” in these patients was similar to that of the other 
group during the 6 months of the study. If the cost of this 
additional medication, which apparently does not provide 
higher effectiveness, was avoided, the result of the cost-ef-
fectiveness analysis and therefore treatment with pregabalin 
alone, rather than with an SSRI/SNRI drug, would still be 
more cost-effective. However, due to the fact that the sample 
size was small (n = 56) and patients were not randomized to 
the two groups, further studies with larger sample should be 
carried out to confirm this hypothesis.
Reviewing the literature on cost-effectiveness studies in 
anxiety disorders to date, we found eight cost-effectiveness 
analyses published on panic disorder, five on GAD, one on 
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Figure 3 Cost-effectiveness acceptability curve.
Abbreviations: WTP, Willingness to pay; QALY, Quality-Adjusted Life Year; Health care costs, (medical visits + hospitalization + non pharmacological treatments + drugs) costs.
Table 5 Results of sensitivity analyses on key model assumptions 
and parameter estimates
Variable Difference in health care  
cost/QALY gain (2008 €)  
[mean (95% CI)]
% re-samples  
below a WTP   
of €30,000
Medical visit costs (€)
×0.5 basecase 21,754 (dominant; 130,557) 86%
×1.5 basecase -40,149 (dominant; 133,765) 86%
Non pharmacological treatment costs (€)
×0.5 basecase 16,019 (dominant; 125,344) 86%
×1.5 basecase -15,276 (dominant; 133,462) 86%
Drug costs (€)
×0.5 basecase -12,383 (dominant; 80,128) 92%
×1.5 basecase 36,619 (dominant; 213,692) 78%
QALY gained
×0.5 basecase -17,605 (dominant; 229,569) 70%
×1.5 basecase 9,550 (dominant; 89,653) 90%
Extension of the  
trial to 12 months
25,864 (dominant; 172,280) 80%
Abbreviations: QALY gained, quality-adjusted life year gained; WTP, Willingness 
to pay.
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social phobia, one on post-traumatic stress disorder, and 
another involving several anxiety disorders.22 Of the five cost-
effectiveness analyses focusing on GAD,23,39–42 three used 
DSM-IV diagnostic criteria for GAD (the others used ICD-10 
codification), and only one of them presented QALY gain as 
a measure of effectiveness, then incorporating both quantity 
and quality of life in a combined summary effectiveness 
measurement. Guest et al examined the cost-effectiveness 
of venlafaxine XL versus diazepam over 6 months from 
the perspective of the UK National Health Service. They 
used a deterministic decision analytic model and reported 
an estimate of the incremental cost for each additional 
patient successfully treated with venlafaxine XL (versus 
diazepam), and an incremental cost for each additional 
patient in whom a relapse would be avoided at 2000/2001 
price levels. They concluded that starting treatment with 
venlafaxine rather than diazepam was more effective clini-
cally and cost-effective for managing nondepressed patients 
with GAD in the UK. The investigators’ CGI improvement 
score was used as the key clinical measure in the model, but 
the authors recognized that CGI measurements might be less 
robust than HAM-A scores.41 Jörgensson et al used a similar 
model and reported higher rates of first-line treatment suc-
cess and lower discontinuation rates due to adverse events 
over 9 months in patients treated with escitalopram (versus 
paroxetine), as well as cost savings (at 2004 price levels) from 
a societal perspective. Treatment success and relapse were 
defined in the model using the CGI alone or in combination 
with HAM-A threshold values and evidence of treatment 
discontinuation due to lack of efficacy. The authors did not 
report estimates of the cost-effectiveness of escitalopram 
versus paroxetine.42 Therefore, there is only one published 
cost-effectiveness analysis using DSM-IV diagnostic criteria 
for GAD, QALY gain as a measure of effectiveness, and a 
third party payer’s perspective comparing pregabalin with an 
SSRI/SNRI drug.23 A particular strength was its stochastic 
(as opposed to deterministic) nature, which takes into con-
sideration the uncertainty inherent in estimates of the average 
change in HAM-A scores with treatment. However, the data 
used were obtained from the short-term (8-week) PEACE 
(Pregabalin Efficacy in Anxiety Clinical Evaluation) trial.43
The strengths of our study are that it is the first analy-
sis involving all the perspectives mentioned above, uses 
a representative sample of 282 patients and, importantly, 
captures real-world outcomes over a period of 6 months. In 
terms of cost, comparing the total health care costs shown 
by our analysis with those in the studies cited above, our 
analysis seems more complete because the costs of all 
  medical visits and hospitalization were included, in   addition 
to   nonpharmacological treatment. As pointed out in a sys-
tematic review published in 2009,44 it would be useful to 
agree on measures of effectiveness used in cost-effectiveness 
analysis, eg, standard measures of QALY gained, or perhaps 
disability-adjusted life years avoided, which is recommended 
in most guidelines for financial evaluation and assessment of 
health technologies.39,45,46 Assuming that any analysis of the 
real situation carries some degree of uncertainty, a sensitivity 
analysis of 10,000 samples using bootstrapping techniques 
was carried out to minimize errors and increase the certainty 
of cost estimates and QALY gained over the total duration of 
the study, thereby determining the robustness of the analysis 
and its conclusions.
However, some limitations of our cost-effectiveness 
analysis approach should be noted. First is the observational 
design of the original cohort data source, ie, the ADAN study, 
with its inherent limitations, in particular, the fact that it was 
not a clinical trial. However, rather than just being considered 
a methodological weakness of our analysis, it could also 
be accepted as an advantage for payers or for the National 
Healthcare Service because the study was based on real-world 
data enabling health decision-makers to estimate actual costs 
and thereby improve resource utilization. Second, the study 
sample size could be considered small, with power below 
80% in effectiveness comparisons, meaning that the study 
may be limited in terms of guaranteeing than differences in 
effectiveness could exist between the two groups of GAD 
therapy analyzed in this study. However, the outcomes used 
in the cost-effectiveness analysis were similar (and not dif-
ferent from a statistical perspective) at baseline. Despite the 
pregabalin group being more severely affected at baseline, 
after 6 months of treatment they had a better quality of life 
gain than the group treated with SSRI/SNRI drugs, indicating 
that the randomized controlled trial did demonstrate a real-
world clinical benefit for pregabalin, and appears to provide 
benefit additional to that seen in patient treated with SSRI/
SNRI drugs. Third, the patients included in this analysis were 
benzodiazepine-refractory and met specific criteria in the 
ADAN study protocol. Although there is no consensus in 
the scientific community on how to define refractory criteria, 
the criteria used here seem to fall within the scope of that 
used in other reports in the literature.3,46,48 Moreover, our 
cost-effectiveness analysis could be criticized for focusing 
on benzodiazepine-refractory outpatients without including 
other types of patients with GAD. While this is true, most 
patients with GAD seen on an outpatient basis in psychiatry 
clinics in Spain fall in the refractory subtype, so the results of 
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this cost-effectiveness analysis would therefore be applicable 
to a considerable number of subjects in seen in standard 
psychiatry clinics. Another possible limitation is the fact 
this evaluation was only from the perspective of the Spanish 
national health system, and did not include indirect costs 
resulting from loss of productivity, which could be significant 
for patients with GAD, nor did it include out-of-pocket costs 
or resources paid for by the patients themselves. The main 
reason for this is that, in the Spanish health care context, the 
national health system is more concerned about the costs of 
the resources it funds rather than the costs of components 
which do not fall within its scope of coverage. Moreover, 
due to the absence of specific questions in the patient diary 
during the study regarding source of funding, some of the 
used or prescribed nonpharmacological treatments in this 
study could have been paid for by the patient, such as some 
types of massage, acupuncture sessions, yoga/tai chi sessions, 
and naturopathy.
In conclusion, despite the limitations of the analy-
sis, pregabalin appears to be cost-effective in com-
parison with SSRI/SNRI drugs in the treatment of 
  benzodiazepine-refractory outpatients with a DSM-IV 
diagnosis of GAD treated in mental health centers in usual 
medical practice in Spain.
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